Longevity Lab Report · Public evidence card
What did VITAL find about fish oil and heart events?
Assessed 2026-11-15 · Main study published 2018-11-10
This card contains the public evidence assessment only.
Conclusion
VITAL did not establish a reduction in its primary cardiovascular outcome. A positive result for prescription EPA in a different population cannot be assumed to apply to an ordinary fish-oil supplement.
- Population and design
- 25,871 US adults: men aged 50+ and women aged 55+, without cardiovascular disease or cancer at enrollment. Randomized, double-blind, placebo-controlled factorial trial.
- Studied intervention
- A daily 1 g marine omega-3 capsule providing 460 mg EPA and 380 mg DHA.
- Comparator
- Olive-oil placebo.
- Measured outcome
- The combined outcome of heart attack, stroke or cardiovascular death. Follow-up: Median 5.3 years.
- Observed result
- 386 versus 419 participants had a primary cardiovascular event. Hazard ratio 0.92 (95% confidence interval 0.80–1.06). Heart attack alone, a secondary endpoint, was lower.
- Main limitations
- The primary and secondary outcomes answer different questions.
- Participants, formulations and comparators differed across the major trials.
Baseline evidence assessment, not a new study or a revised library grade. This card contains no personal responses and does not recommend treatment.
Sources
- VITAL (Manson et al., 2019)
Main study · Published 2018-11-10 · Checked 2026-11-15 · DOI 10.1056/NEJMoa1811403
Primary publication abstract and indexed results
- REDUCE-IT (Bhatt et al., 2019)
Context · Published 2018-11-10 · Checked 2026-11-15 · DOI 10.1056/NEJMoa1812792
Primary publication abstract and indexed results
- STRENGTH (Nicholls et al., 2020)
Context · Published 2020-11-15 · Checked 2026-11-15 · PMID 33190147
Full primary publication via indexed PMC text
Public card: https://longevitylabreport.com/research/omega-3-vital/card
Full explainer, context and assessment history